anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the time frame July 1, 2013 through September 30, 2014, 300 infants with NAS have been cared for in the JHACH NICU with an average length of stay of 30 days. Such a prolonged length of stay has a negative impact on maternal/infant bonding. In addition, infants suffering from NAS have poor regulatory mechanisms and are invariably hard to care for and difficult to console, and they provide an emotional challenge to their caretakers. This challenge becomes even more significant when the caretaker is the mother who is suffering from addiction and is already emotionally compromised by feelings of depression, anxiety, guilt or insecurity. Attachment is an ongoing process and the quality of the relationship between mother and her infant directly influences the structure of the child's affective ties and overall organization of responses to environment. This mother-infant bond sets the stage for understanding and identifying the infant's needs and reciprocal parental response to those needs. Maternal emotional unavailability has potentially serious effects on the long term mother-child relationship, and on the child's development.

This project provides a novel approach and an alternative care plan for infants with NAS. It is funded by the State of Florida and allows to: 1) educate and empower a specified population of mothers who are undergoing institutionalized rehabilitation and whose infant needs treatment for NAS; 2) safely transition the infants home for final wean of their pharmacologic treatment; 3) provide regular developmental follow up for these infants through our NICU follow up clinic, hence identifying and quickly responding to neuro-developmental delays.
An understanding of the health inequities that surround the treatment and prevention of COPD is required to address the barriers that hinder improvement of care for underserved populations. This scoping review was conducted to identify the existing evidence of social factors that affect the health, health-care access, and health-care quality of patients with COPD within the United States, and to identify gaps in knowledge to help direct future research. We followed the guidelines from the Joanna Briggs Institute and Preferred Reporting Items for Systematic reviews and Meta Analyses Extension for Scoping Reviews. In July 2022, a literature search by using Ovid (Embase) and MEDLINE (PubMed) databases was conducted to identify articles on COPD, published between 2016 and 2021, written in English, and that investigated at least one health inequity as defined by the National Institutes of Health. All studies were screened for inclusion criteria and were extracted in a masked, duplicate manner. Each health inequity was investigated, extracted, and summarized. Thirty articles were screened in full text, and 19 were found to meet inclusion criteria. Common social factors investigated in the COPD literature included race/ethnicity, income, and education. Since the implementation of the National Institutes of Health's sex and gender minority category in 2016, only one study within our sample examined LGBTQ+ (lesbian, gay, bisexual, transgender, queer [or sometimes questioning], and others) patients with COPD. The least commonly investigated social factors that affect patients with COPD were rural/under-resourced (geography), sex and gender, and LGBTQ+ affiliation. In addition, occupational status was not investigated by any included studies in our sample. Our scoping review underlines the lack of research with regard to inequities that affect patients with COPD. We propose researching hormone replacement therapy's impact on lung function in transgender and nonbinary patients with COPD. Implementation science studies are suggested to enhance intervention for COPD medication adherence among racial/ethnic minority groups, given the intersectionalities of social factors that disproportionately affect this population. We, also recommend developing telemedicine pulmonary rehabilitation technology for rurally located patients with COPD.
Respiratory syncytial virus (RSV) is the most important viral respiratory pathogen in children. Infection due to RSV represents a large public health burden; in Canada, it accounts for 5,800 hospitalizations annually. The peak incidence of RSV disease occurs between 2-6 months of age with half of all infants infected in the first year of life. Palivizumab has been approved for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high-risk of RSV disease. These children include those born premature, those with bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD).

With the recent approval of palivizumab in Canada, access to this medication has increased. However, there are limited data on utilization, compliance, and health outcomes, particularly the frequency and severity of RSV infections. The primary objective of this study is to provide insight into the current management (utilization, compliance) of children at high-risk of RSV infection with palivizumab prophylaxis in the tertiary care centers and community settings through the development of a Canadian Registry Database.
A drug delivery system is provided. The drug delivery system can include a drug delivery device configured to store and deliver a drug to a user and a drug delivery management device for managing operation of the drug delivery device. The drug delivery management device can determine information relating to the drug that is to be provided to the user. The information relating to the drug can be provided by an indicator coupled to a container configured to store the drug. The drug delivery management device can determine a software program for controlling operation of the drug delivery management device based on the determined information relating to the drug. Other embodiments are disclosed and described.
Sarcosine (also called N-methylglycine) is an endogenous GlyT-1 inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function. NMDA receptor, a subtype of ionotropic glutamate receptors, serves important functions in the brain, including learning, memory, cognition, and neural plasticity under physiological conditions and contributes to neurodegeneration in pathophysiological processes. NMDA receptor represents collectively a group of heteromeric tetramers. Every NMDA receptor is a protein complex, typically composed of two NR1 subunits and two NR2 subunits that together form the NMDA receptor ion channel. It requires two receptor agonists (glutamate for the NR2 binding site and glycine for the NR1 binding site) to open the ion channel for NMDA receptor activation. Clinically, modulation through the NMDA-NR1-glycine site is preferred to avoid the excitotoxicity associated with the glutamate site activation.8 In addition, recent animal studies have shown that dopamine secretion can be enhanced by either blocking the striatal NR2 or by activation of the NMDA-receptor glycine site. In the project, we will focus on pharmacological enhancement of NMDA-glycine receptor function based on increasing synaptic glycine concentration by sarcosine administration to examine whether enhancing NMDA-glycine receptor activity can improve the neuropsychiatric symptoms, cognition and hopefully motor function in PD-D patients
PURPOSE:The titled activator comprising a culture mixture of a mycelium of Ganoderma lucidum (Fr.) Karst. obtained by cultivating it in a liquid medium containing glucose and an embryo bud of wheat. CONSTITUTION:5-10 mg/100 mycelium of Ganoderma lucidum (Fr.) Karst (Gnoderma lucidum (Fr.) Karst. of Polyporaceae of Aphyllophorales, belonging to the genus Basidomycetes, may be used) is inoculated into a liquid medium containing 0.2-10w/v, preferably 1-8w/v% glucose and 0.2-2w/v%, preferably 0.5-1.0w/v% embryo bud of wheat, cultivated at 25-30 deg.C at 0.5-3.0v.v.m aerated amount for 7-21 days in a dark place, to give a culture mixture of mycelium of Ganoderma lucidum (Fr.) Karst. in high yield. A phagocyte function activator containing it is obtained. This activator is effective for remedying infectious diseases such as Chediak-Higashi syndrome, REIJI leukocyte syndrome, etc. and malignant tumor. Preferably a dose is 50-3,000mg in case of extracted powder, and 100-5,000mg in case of concentrated and dried material from the culture mixture.
BACKGROUND: Dairy products and their components may impact immune function, although the current evidence base has some research gaps. As part of a larger systematic literature review of dairy products/components (including probiotics, dairy proteins, and dairy fats) and immune function, we identified the available epidemiologic research on the impact of dairy products/components on incidence and natural history of infectious diseases.
METHODS: PubMed and Embase databases were systematically searched through May 2022 to identify eligible studies using pre-defined Population, Intervention, Comparator, Outcomes, and Study design criteria. Herein, we focused on describing the impacts of dairy product/component on infectious disease outcomes, including the effect on leukocyte and cytokine response in humans. Risk of bias assessment was performed using the Academy of Nutrition and Dietetics Quality Criteria Checklist. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed.
RESULTS: Among 9,832 studies identified from the larger literature search, 133 relevant publications from 128 studies reported on dairy product/component and infectious disease outcomes. Few studies are available on the impact of non-fermented milk and traditional yogurt on infectious disease. Evidence was identified to suggest milk and yogurt drinks fermented with Lactobacillus strains reduce the risk and burden of common infectious diseases (CIDs), although the findings are mixed and difficult to reconcile due to heterogenous study populations, bacterial strains, and study methods. Few studies are available on the impact of dairy products/components on the natural history of infection, with the available findings indicating probiotics may both improve gastrointestinal symptoms among HIV-infected persons and help eradicate and alleviate the symptoms of Heliobacter (H.) pylori. The available evidence also suggests lactoferrin may reduce the virological burden of COVID-19 and hepatitis C virus. No consistent changes in leukocytes or cytokine production were observed for any type of dairy product or their components, but probiotics appeared to enhance natural killer cell levels/activity and the phagocytic process.
CONCLUSIONS: Dairy products, particularly those with added probiotics, may represent an easily accessible nutritional intervention to prevent and improve the course of infectious diseases. This review highlights the need for additional research in this potentially impactful area.
PROSPERO REGISTRATION: CRD42022333780.
New biological substances are obtained according to the parent patent FR2491334 (Derwent Basic EP--49666, 31399E/16) by treatment of solubilised and delipidated human casein with trypsin, using an enzyme/substrate ratio of 1/100 for 24 hrs. at 37 deg.C and then after centrifugation, fractionating the water-soluble products on Sephadex G50 (RTM) and eluting with 30% acetic acid to isolate the active cpds., the process is characterised in that the substance having average mol. wt. of 2200 (fraction V of the parent patent) is filtered through DEAE Sephadex A-25 (RTM) and eluted with a buffer of decreasing pH to isolate a basic substance MJH-24 and two acid substances MJH-63 and MJH-65. Immunological agents, which in vitro favour the prodn. of antibodies and accelerate phogocytosis. The three substances show good activity against experimental Kbebsiella pneumoniae infections in mice, when administered I.V. at 0.05 mg/kg.
INTRODUCTION: The treatment of a chronic type B aortic dissection can be challenging and need a precise and multidisciplinary planning.
MATERIALS AND RESULTS: A 62-year-old man presented to our hospital with acute aortic thrombosis on chronic thoracoabdominal dissection with bowel and kidney ischemia. He was submitted to urgent open surgical treatment with replacement of thoracoabdominal aorta and reimplantation of celiac trunk, superior mesenteric artery and right renal artery. During the intervention the visceral perfusion was provided with a modified Gott shunt; while the lower limb perfusion was provided by an existing right axillo-femoral and femoro-femoral bypass. The patient had a favorable course and did not report any complications.
CONCLUSION: The ideal management strategy of complex post-dissection conditions has to be tailored on the single patient's features to provide the maximal efficacy and safety. If the endovascular treatment is not viable, open surgery represents a valid option.
Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face \[F2F\] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up.
The present invention relates to an oncolytic virus having improved safety and anticancer effects and use thereof. The oncolytic virus of the present invention having improved safety and anticancer effects can be obtained by inserting a gene encoding an HSV-TK fragment into a TK gene region to delete TK of vaccinia virus. In addition, the oncolytic virus of the present invention expresses an HSV-TK fragment to phosphorylate GCV, thereby killing cancer cells infected by the oncolytic virus, and even cancer cells in their vicinity. In addition, GCV is also involved in the inhibition of virus proliferation, and thus side effects caused by viruses can be controlled even by administering a high dose of viruses. Furthermore, even if the number of virus particles is reduced due to the inhibition of the anti-viral proliferation by GCV, the anti-cancer effect is improved. Therefore, the oncolytic virus of the present invention, which has improved safety and anticancer effects, can be effectively used for the treatment of cancer.
Deferiprone Tablets contain 1,000 mg or 500 mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. The molecular formula for deferiprone is C 7H 9NO 2and its molecular weight is 139.15 g/mol. Deferiprone has the following structural formula: 

Deferiprone is a white to pinkish-white powder. It is sparingly soluble in deionized water (14.3 mg/mL) and has a melting point range of 272°C to 278°C.

Deferiprone Tablets (three times a day), 1,000 mg

White, film-coated, oval shaped tablets; imprinted with "T" score "1 K" on one side and plain on the other. The tablets can be broken in half along the score line. Each tablet contains 1,000 mg deferiprone and the following inactive ingredients: Tablet core - crospovidone, magnesium stearate and methylcellulose; Coating - copovidone, hypromellose, medium chain triglycerides, polydextrose, polyethylene glycol and titanium dioxide.

Deferiprone Tablets 500 mg

White to pinkish-white, capsule-shaped tablets; scored on one side, engraved "T" on the left of the score line and "5" on the right and plain on the other side. The tablets can be broken in half along the score line. Each tablet contains 500 mg deferiprone and the following inactive ingredients: Tablet core - colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.
Serious adverse reactions that may be associated with morphine sulfate extended-release therapy in clinical use are those observed with other opioid analgesics and include: respiratory depression, respiratory arrest, apnea, circulatory depression, cardiac arrest, hypotension, and/or shock (seeOVERDOSAGE, WARNINGS).

The less severe adverse events seen on initiation of therapy with morphine sulfate extended-release are also typical opioid side effects. These events are dose dependent, and their frequency depends on the clinical setting, the patient's level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent of these include drowsiness, dizziness, constipation and nausea. In many cases, the frequency of these events during initiation of therapy may be minimized by careful individualization of starting dosage, slow titration, and the avoidance of large rapid swings in plasma concentrations of the opioid. Many of these adverse events, will cease or decrease as morphine sulfate extended-release therapy is continued and some degree of tolerance is developed, but others may be expected to remain troublesome throughout therapy.
The present invention relates to a Qianlieshuqing Chinese medicine preparation for treating chronic prostatitis and a preparation method thereof. The Chinese medicine preparation is composed of the following medicinal components by the weight ratio: 8.0 to 22.0 portions of selfheal spike, 6.0 to 15.0 portions of lilac pink herb, 5.0 to 14.0 portions of red peony root, 6.0 to 15.0 portions of plantain seed, 5.0 to 14.0 portions of red sage root, 6.0 to 14.0 portions of dandelion and 4.0 to 9.0 portions of desertliving cistanche. In the Qianlieshuqing Chinese medicine preparation for treating chronic prostatitis provided by the present invention, effective components in raw medicinal materials are extracted by a combination method of ethanol extraction and water boiling extraction, and the activity of the effective components is maintained. In this way, the dissolution of the effective components in the medicines is greatly increased, and the preparation is favorable to the absorption of the medicines; thus, the biological availability of the preparation can be enhanced. In addition, the preparation of the present invention is a pure Chinese medicine preparation, and thus, after being taken by patients for a long period of time, the preparation has the advantages of no toxic or side effect and good safety. In addition, the present invention has the advantages of simple preparation technology and convenient operation.
1. A method for treatment patients in need an acquired hypercoagulable state or acquired protein C deficiency by administering by continuous infusion for about 24 to about 144 hours a dosage of about 20 mkg/kg/hr to about 50 mkg/kg/hr of human activated protein C. 2. A method according to Claim 1 wherein said hypercoagulable state or protein C deficiency is associated with sepsis. 3. A method according to Claim 1 wherein said hypercoagulable state or protein C deficiency is associated with purpura fulminans. 4. A method according to Claim 1 wherein said hypercoagulable state or protein C deficiency is associated with meningococcemia. 5. A method according to Claim 4 wherein said human patient is a juvenile. 6. A method according to Claim 1 wherein said hypercoagulable state or protein C deficiency is associated with burns. 7. A method according to Claim 1 wherein said method of treatment or prevention is for humans suffering from venous thromboembolic complications associated with bone marrow and other organ transplantations. 8. A method according to Claim 1 wherein said method of treatment or prevention is for humans suffering from venous thromboembolic complications associated with surgery or trauma. 9. A method according to Claim 1 wherein said method of treatment is for humans suffering with an acquired hypercoagulable state or protein C deficiency associated with complications during pregnancy. 10. A method according to Claim 1 wherein said hypercoagulable state or protein C deficiency is associated with ARDS. 11. A method according to Claim 1, which comprises administering to said patient by continuous infusion about 36 to about 120 hours a dosage of about 20 mkg/kg/hr to about 50 mkg/kg/hr of human activated protein C. 12. A method according to Claim 11, which comprises administering to said patient by continuous infusion about 48 to about 96 hours a dosage of about 20 mkg/kg/hr to about 50 mkg/kg/hr of human activated protein C. 13. A method according to Claim 12, which comprises administering to said patient a dosage of about 22 mkg/kg/hr to about 30 mkg/kg/hr of human activated protein C. 14. A method according to Claim 13, which comprises administering to said patient a dosage of about 24 mkg/kg/hr of human activated protein C. 15. A method for treatment patients in need an acquired hypercoagulable state or acquired protein C deficiency by administering by continuous infusion for about 24 to about 144 hours an effective amount of human activated protein C to achieve activated protein C plasma levels in the range of 2 ng/ml to 200 ng/ml.
ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
FIELD: medicine, hormones, peptides. SUBSTANCE: invention relates to novel antagonists of luteinizing hormone releasing factor, first of all, to peptidomimetics and peptides with modified side-chain of the formula (V): R 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 6 ,R 7  where D -Xxx, R 8  and   are characterized in the invention claim and their salts with pharmaceutically acceptable carrier. Invention describes also therapeutic use of these compounds as analog of luteinizing hormone releasing factor showing high antagonistic activity and without nonfavorable adverse effects, especially, they do not stimulate edemas. Invention describes also method of synthesis of compound of the formula (V) by solid-phase method or partially solid-phase method and preparing therapeutic composition showing high affinity to receptors of luteinizing hormone releasing factor that involves compounds by p. p. 1-4 as an active substance. Invention describes also method of preparing medicinal preparations containing compounds by p. p. 1-9 where these compounds are mixed with accessory substances. EFFECT: new antagonists indicated above, improved method of synthesis and preparing. 17 cl, 7 tbl, 6 dwg, 3 sch, 85 ex
This application discloses a method and system for pneumonia area detection. The method includes obtaining a medical image to be processed. Processing the medical image to be processed through preset image preprocessing method to obtain a standard format image. Obtaining a frame size of an original pneumonia area. Processing the frame size of the original pneumonia area through preset algorithm and the standard format image to obtain a frame size of a standard pneumonia area. Inputting the standard format image and the frame size of the standard pneumonia area into a pneumonia area detecting model to obtain an output pneumonia area. The method confirms frame and size of pneumonia area, which can identify pneumonia area accurately and reduce workload for identification.
Treatments for Alzheimer's disease have primarily focused on removing brain amyloid plaques to improve cognitive outcomes in patients. We developed small compounds, known as BK40143 and BK40197, and we hypothesize that these drugs alleviate microglial-mediated neuroinflammation and induce autophagic clearance of neurotoxic proteins to improve behavior in models of neurodegeneration. Specificity binding assays of BK40143 and BK40197 showed primary binding to c-KIT/Platelet Derived Growth Factor Receptors (PDGFR)α/β, whereas BK40197 also differentially binds to FYVE finger-containing phosphoinositide kinase (PIKFYVE). Both compounds penetrate the CNS, and treatment with these drugs inhibited the maturation of peripheral mast cells in transgenic mice, correlating with cognitive improvements on measures of memory and anxiety. In the brain, microglial activation was profoundly attenuated and amyloid-beta and tau were reduced via autophagy. Multi-kinase inhibition, including c-KIT, exerts multifunctional effects to reduce neurodegenerative pathology via autophagy and microglial activity and may represent a potential therapeutic option for neurodegeneration.